Unilife and Stason Pharmaceuticals Sign Agreement for Unitract 1mL Safety Syringe

Unilife Corporation announced it has signed an exclusive five-year agreement with Stason Pharmaceuticals Inc. to market the Unitract 1mL safety syringe in Japan, China, and Taiwan.  Stason's Taiwan-based strategic alliance affiliate, Standard Chem. and Pharm. Co., LTD will act as the primary distributor of the product within these designated territories.

Stason CEO Harry Fan stated: "We believe strongly in the market for the Unitract safety syringe and its potential to help decrease needlestick injuries around the world. We are excited to be one of the first distributors of this revolutionary device and to have the opportunity to exclusively distribute the Unitract syringe to our customers in Asia.
 
“In particular, we believe there are significant opportunities for pharmaceutical companies to gain a competitive market advantage by supplying their injectable drugs in kits containing the drug vial and units of the Unitract 1mL Syringe," Fan said.
 
"This strategic alliance with Unilife also represents our joint vision where drugs and devices come together to deliver medications more comfortably to patients and more safely for hospital staff," added Stason vice president, corporate development Diana Wood.
 
Unilife CEO Alan Shortall said: "With manufacturing of our Unitract1mL syringes underway at our FDA-certified facility in Pennsylvania, we are excited to move forward with this initial distribution agreement and initial order for one million Unitract safety syringes with Stason Pharmaceuticals and Standard Chem. and Pharma.
 
“We believe there is a significant market opportunity for our safety syringes throughout the Asia-Pacific region, especially within fast-growing nations where there is both an appreciation for innovative US-manufactured technology and a desire to use premium safety medical devices which can minimize the transmission of blood-borne pathogens such as HIV and hepatitis C within healthcare facilities,” Shortall said.
 
"We are also continuing to negotiate with other pharmaceutical and healthcare companies across the world for distribution rights for the Unitract 1mL syringes. We expect that additional agreements will be signed in conjunction with the continued global rollout of the Unitract 1mL syringes," he added.
 
The agreement includes a requirement for Stason to purchase a minimum of one million units of the Unitract 1mL syringe per year during the term of the contract. Stason is placing an immediate annual order with Unilife for the purchase of one million units of the Unitract 1mL syringe. Other countries within South-East Asia may be added to the list of designated territories where Stason has exclusive rights to sell the product if the parties reach agreement on minimum orders for those countries.
 
The Unitract(TM) range of 1mL syringes is the world's first and only known syringe that allows operators to control the speed of automatic needle retraction directly from the patient's body into the barrel of the syringe where it is locked in place, Unilife said.
 
No votes yet